转甲状腺素蛋白心脏淀粉样变性中[99mTc]Tc-DPD SPECT/CT定量评估右心室淀粉样负荷的临床意义
研究纳入76例转甲状腺素蛋白心脏淀粉样变性(ATTR-CA)患者,用定量[99mTc]Tc-DPD SPECT/CT评估右心室(RV)摄取,发现弥漫性RV摄取者室间隔厚度、心肌细胞外容积(ECV)和肌钙蛋白T更高,RV摄取与上述指标及左心室(LV)摄取、NT-proBNP相关;53例随访中位16个月,高LV和RV摄取显著预测主要不良心脏事件(MACEs);20例接受Tafamidis治疗者LV和RV摄取显著下降。
要点
- 定量[99mTc]Tc-DPD SPECT/CT可评估ATTR-CA患者右心室淀粉样负荷。
- 弥漫性RV摄取与更高的室间隔厚度、ECV和肌钙蛋白T相关。
- 高LV和RV摄取显著预测MACEs,Tafamidis治疗后LV和RV摄取显著下降。
核心结论
- SPECT/CT定量的RV淀粉样负荷增加与疾病晚期阶段相关,并可预测MACEs,可作为ATTR-CA预后和治疗监测的有价值标志物。
研究设计与样本
- 连续纳入ATTR-CA患者,行定量[99mTc]Tc-DPD SPECT/CT,用SUVmax和TBR量化心室淀粉样负荷,评估RV摄取(局灶性或弥漫性)与临床特征及心脏磁共振(CMR)数据的关联。
- 主要终点为MACEs,包括全因死亡、心力衰竭住院、完全性房室传导阻滞、持续性室性心动过速和心房颤动/扑动,采用Cox回归和Kaplan-Meier生存分析评估预后关联。
- 次要终点为Tafamidis治疗期间的纵向SPECT/CT分析。
主要发现
- 研究纳入76例患者,SPECT显像均显示RV和LV摄取。
- 与局灶性RV摄取患者相比,弥漫性RV摄取患者血清肌钙蛋白T水平更高(P < 0.05)、室间隔厚度更大(P < 0.01)、心肌细胞外容积(ECV)更高(P < 0.05)。
- RV摄取与室间隔厚度、ECV、LV摄取、NT-proBNP和肌钙蛋白T相关(均P < 0.05)。
- 53例患者中,高LV和RV摄取显著预测MACEs(P < 0.001),中位随访时间16个月。
- 20例患者亚组在Tafamidis治疗后LV和RV摄取显著降低(P < 0.001)。
关键数值与推荐
- 弥漫性RV摄取组较局灶性RV摄取组:血清肌钙蛋白T水平更高(P < 0.05)、室间隔厚度更大(P < 0.01)、ECV更高(P < 0.05)。
- RV摄取与室间隔厚度、ECV、LV摄取、NT-proBNP和肌钙蛋白T相关(均P < 0.05)。
- 53例患者中高LV和RV摄取显著预测MACEs(P < 0.001),中位随访16个月。
- 20例患者Tafamidis治疗后LV和RV摄取显著降低(P < 0.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate right ventricular (RV) uptake measured by quantitative [99mTc]Tc-DPD SPECT/CT to investigate its role in predicting and evaluating prognosis and therapeutic outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CA). METHODS: Patients with ATTR-CA were consecutively enrolled for quantitative [99mTc]Tc-DPD SPECT/CT. Ventricular amyloid burden was quantified by SUVmax and TBR. Differences in RV uptake (focal or diffuse) and associations with clinical characteristics and CMR data were evaluated. The primary endpoint was major adverse cardiac events (MACEs), including all-cause deaths, heart failure hospitalizations, complete atrioventricular block, sustained ventricular tachycardia, and atrial fibrillation/flutter. Prognostic associations were evaluated using Cox regression and Kaplan-Meier survival analysis. A secondary endpoint involved a longitudinal SPECT/CT analysis during Tafamidis therapy. RESULTS: The study included 76 patients, all showing both RV and LV uptake on SPECT imaging. Compared with patients with focal RV uptake, patients with diffuse RV uptake had higher serum troponin T levels (P < 0.05), septal thickness (P < 0.01), and external cardiac circulation volume (ECV) (P < 0.05). RV uptake was correlated with septal thickness, ECV, LV uptake, NT-proBNP and troponin-T (all P < 0.05). Among 53 patients, high LV and RV uptake significantly predicted MACEs (P < 0.001), with a median follow-up time of 16 months. A subgroup of 20 patients showed significant reductions in LV and RV uptake after Tafamidis treatment (P < 0.001). CONCLUSION: Increasing RV amyloid burden quantified by SPECT/CT is associated with advanced disease stage and predicts MACEs, serving as valuable markers for prognosis and treatment monitoring in ATTR-CA.
引用
- Zhao M, Calabretta R, Binder P, et al. Clinical significance of quantitative assessment of right ventricular amyloid burden with [99mTc]Tc-DPD SPECT/CT in transthyretin cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2024. PMID: 39586845. doi:10.1007/s00259-024-06981-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。